Clinical Paths for Soluble Epoxide Hydrolase Inhibitors

82.8K

views

98

authors

17

articles

Editorial

25 September 2020

Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors

John D. Imig

and

Christophe Morisseau

4,181 views

8 citations

Editors

2

University of Arkansas for Medical Sciences

Christophe Morisseau

University of California, Davis

Impact

About

Soluble epoxide hydrolase (sEH) is an enzyme that contributes importantly to metabolism of endogenous, biologically active lipids including epoxides of arachidonic acid (EETs). Soluble epoxide hydrolase inhibitors (sEHIs) were developed as a means to increase lipid epoxide-including epoxyeicosatrienoic acids (EETs) and sEHIs were found to reduce blood pressure, improve insulin sensitivity, and decrease inflammation. Further sEHI development led to initial clinical trials for hypertension and diabetes. More recently, there has been significant expansion of the potential clinical paths for sEHIs. including clinical trials for COPD, with positive initial findings demonstrating improved endothelial function in smokers with COPD.

There have also been great advances in sEHI development in the areas of CKD and neuropathic pain - with clinical trials scheduled to begin in 2019 targeting diabetic neuropathic pain.

This Research Topic seeks to capture the increasingly broad scope for the potential applications of sEHIs, covering pulmonary, kidney, diabetes, and neural pathologies. Research publications will span preclinical animal studies, early stage clinical trials, and exciting results from completed clinical trials. We would also welcome the submission of industry-based articles. In doing so, this Research Topic hopes to make a significant contribution to the exciting drug development movement for sEHIs to treat human diseases.

Soluble epoxide hydrolase (sEH) is an enzyme that contributes importantly to metabolism of endogenous, biologically active lipids including epoxides of arachidonic acid (EETs). Soluble epoxide hydrolase inhibitors (sEHIs) were developed as a means to increase lipid epoxide-including epoxyeicosatrienoic acids (EETs) and sEHIs were found to reduce blood pressure, improve insulin sensitivity, and decrease inflammation. Further sEHI development led to initial clinical trials for hypertension and diabetes. More recently, there has been significant expansion of the potential clinical paths for sEHIs. including clinical trials for COPD, with positive initial findings demonstrating improved endothelial function in smokers with COPD.

There have also been great advances in sEHI development in the areas of CKD and neuropathic pain - with clinical trials scheduled to begin in 2019 targeting diabetic neuropathic pain.

This Research Topic seeks to capture the increasingly broad scope for the potential applications of sEHIs, covering pulmonary, kidney, diabetes, and neural pathologies. Research publications will span preclinical animal studies, early stage clinical trials, and exciting results from completed clinical trials. We would also welcome the submission of industry-based articles. In doing so, this Research Topic hopes to make a significant contribution to the exciting drug development movement for sEHIs to treat human diseases.

Download ebook

Share

Editors

University of Arkansas for Medical Sciences

Christophe Morisseau

University of California, Davis

Impact

82,754 Total views

56,591 Article views

22,630 Article downloads

3,533 Topic views

Published In

Journal Thumbnail

Frontiers in Pharmacology

Translational Pharmacology

Journal Thumbnail

Frontiers in Physiology

Integrative Physiology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic